Table 1 Meta-analysis of the APOA5 -1131T>C polymorphism and blood lipids association
Group and subgroups under analysis | Comparisons (n) | Q test Pvalue | SMD (95% CI) | P |
|---|---|---|---|---|
TC | ||||
   All | 42 | 0.42 | 0.08 (0.05, 0.11) | <0.00001 |
   All in HWE | 39 | 0.30 | 0.08 (0.04, 0.12) | 0.0001 |
   No lipid-lowering medicine | 20 | 0.47 | 0.08 (0.03, 0.14) | 0.003 |
   No lipid-lowering medicine in HWE | 19 | 0.41 | 0.08 (0.02, 0.14) | 0.005 |
   European | 16 | 0.16 | 0.07 (-0.00, 0.15) | 0.05 |
   European in HWE | 14 | 0.09 | 0.07 (-0.02, 0.16) | 0.11 |
   East Asian | 18 | 0.69 | 0.09 (0.05, 0.13) | <0.0001 |
   East Asian in HWE | 17 | 0.63 | 0.09 (0.04, 0.15) | 0.0003 |
   Other | 8 | 0.45 | 0.04 (-0.03, 0.11) | 0.23 |
   Healthy | 8 | 0.45 | 0.04 (-0.04, 0.13) | 0.31 |
   Type 2 diabetes | 7 | 0.64 | 0.11 (-0.01, 0.23) | 0.07 |
   CHD | 6 | 0.71 | 0.06 (-0.03, 0.15) | 0.18 |
   CHD in HWE | 5 | 0.58 | 0.06 (-0.04, 0.15) | 0.22 |
   Male | 6 | 0.29 | 0.02 (-0.09, 0.13) | 0.67 |
   Male in HWE | 5 | 0.20 | 0.03 (-0.12, 0.17) | 0.74 |
TG | ||||
   All | 60 | 0.0003 | 0.31 (0.27, 0.34) | <0.00001 |
   All in HWE | 58 | 0.004 | 0.31 (0.28, 0.35) | <0.00001 |
   No lipid-lowering medicine | 28 | 0.35 | 0.33 (0.29, 0.38) | <0.00001 |
   No lipid-lowering medicine in HWE | 27 | 0.32 | 0.33 (0.29, 0.38) | <0.00001 |
   European | 21 | 0.29 | 0.36 (0.29, 0.43) | <0.00001 |
   European in HWE | 20 | 0.26 | 0.36 (0.29, 0.43) | <0.00001 |
   East Asian | 23 | 0.001 | 0.34 (0.29, 0.39) | <0.00001 |
   East Asian in HWE | 22 | 0.10 | 0.35 (0.30, 0.39) | <0.00001 |
   Other | 16 | 0.27 | 0.21 (0.16, 0.26) | <0.00001 |
   Healthy | 8 | 0.89 | 0.36 (0.27, 0.44) | <0.00001 |
   Type 2 diabetes | 7 | 0.77 | 0.40 (0.29, 0.52) | <0.00001 |
   CHD | 6 | 0.88 | 0.39 (0.29, 0.48) | <0.00001 |
   CHD in HWE | 5 | 0.81 | 0.38 (0.28, 0.48) | <0.00001 |
   Male | 10 | 0.39 | 0.26 (0.19, 0.33) | <0.00001 |
   Female | 7 | 0.13 | 0.21 (0.11, 0.31) | <0.0001 |
   Larger | 25 | 0.009 | 0.26 (0.22, 0.30) | <0.00001 |
   Larger in HWE | 24 | 0.05 | 0.27 (0.23, 0.31) | <0.00001 |
LDL-C | ||||
   All | 37 | 0.010 | 0.03 (-0.02, 0.07) | 0.22 |
   All in HWE | 34 | 0.009 | 0.02 (-0.02, 0.07) | 0.34 |
   No lipid-lowering medicine | 16 | 0.32 | 0.02 (-0.05, 0.08) | 0.61 |
   No lipid-lowering medicine in HWE | 15 | 0.26 | 0.02 (-0.05, 0.09) | 0.58 |
   European | 11 | 0.01 | -0.00 (-0.10, 0.10) | 0.99 |
   European in HWE | 9 | 0.005 | -0.01 (-0.14, 0.12) | 0.93 |
   East Asian | 20 | 0.04 | 0.04 (-0.01, 0.10) | 0.14 |
   East Asian in HWE | 19 | 0.05 | 0.04 (-0.03, 0.10) | 0.25 |
   Other | 6 | 0.44 | 0.02 (-0.06, 0.09) | 0.68 |
   Healthy | 8 | 0.03 | 0.05 (-0.09, 0.18) | 0.50 |
   Type 2 diabetes | 8 | 0.11 | 0.04 (-0.09, 0.16) | 0.55 |
   CHD | 5 | 0.73 | -0.03 (-0.12, 0.07) | 0.55 |
   CHD in HWE | 4 | 0.57 | -0.03 (-0.13, 0.07) | 0.56 |
   Male | 5 | 0.02 | -0.06 (-0.25, 0.13) | 0.51 |
   Male in HWE | 4 | 0.02 | -0.09 (-0.34, 0.15) | 0.47 |
HDL-C | ||||
   All | 48 | 0.003 | -0.17 (-0.21, -0.14) | <0.00001 |
   All in HWE | 45 | 0.003 | -0.17 (-0.21, -0.14) | <0.00001 |
   No lipid-lowering medicine | 24 | 0.003 | -0.20 (-0.27, -0.13) | <0.00001 |
   No lipid-lowering medicine in HWE | 23 | 0.002 | -0.20 (-0.28, -0.13) | <0.00001 |
   European | 13 | 0.03 | -0.15 (-0.24, -0.06) | 0.002 |
   European in HWE | 11 | 0.01 | -0.16 (-0.27, -0.05) | 0.006 |
   East Asian | 25 | 0.07 | -0.20 (-0.24, -0.16) | <0.00001 |
   East Asian in HWE | 24 | 0.07 | -0.19 (-0.24, -0.15) | <0.00001 |
   Other | 10 | 0.13 | -0.14 (-0.22, -0.06) | 0.0008 |
   Healthy | 8 | 0.29 | -0.17 (-0.26, -0.07) | 0.0007 |
   Type 2 diabetes | 9 | 0.36 | -0.18 (-0.28, -0.09) | 0.0002 |
   CHD | 5 | 0.003 | -0.21 (-0.42, -0.01) | 0.06 |
   CHD in HWE | 4 | 0.002 | -0.24 (-0.48, -0.01) | 0.06 |
   Male | 6 | 0.55 | -0.11 (-0.20, -0.02) | 0.02 |
   Male in HWE | 5 | 0.41 | -0.11 (-0.21, -0.00) | 0.05 |